Genenta Sciences
Jul 04, 2023
First Gene Therapy for Severe Hemophilia A; FDA Approves CellTrans’s Type 1 Diabetes Cellular Therapy; FDA Approve Amneal’s Parkinson’s Drug Over Safety Concerns; NLS Pharmaceutics’s Phase III Clinical Trials of Quilience; Genenta Science’s Temferon for the Treatment of Glioma; FDA Fast Track Designation to GSK’s Gonorrhea Drug
FDA Approves First Gene Therapy for Severe Hemophilia A BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, announced that the US Food and Drug Administration (FDA) has approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the tr...
Read More...
Sep 12, 2019
Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership
Mallinckrodt has announced to sell its Canadian drug manufacturing BioVectra Inc. to a Miami-based private equity firm, an affiliate of H.I.G. Capital for approximately USD 250 Million. The agreement included a fixed amount of USD 175 Million, with an upfront amount of USD 135 Million, a long term payment of US...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
